InMed Pharmaceuticals Announces $5M Registered Direct And Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that it has